MOR Stock - MorphoSys AG
Unlock GoAI Insights for MOR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $238.28M | $278.27M | $179.60M | $327.70M | $71.76M |
| Gross Profit | $179.92M | $229.65M | $147.40M | $318.52M | $59.67M |
| Gross Margin | 75.5% | 82.5% | 82.1% | 97.2% | 83.2% |
| Operating Income | $-252,475,802 | $162.26M | $-277,600,000 | $119.41M | $-105,120,108 |
| Net Income | $-189,734,199 | $-151,057,591 | $-514,500,000 | $97.89M | $-103,014,058 |
| Net Margin | -79.6% | -54.3% | -286.5% | 29.9% | -143.6% |
| EPS | $-1.38 | $-1.10 | $-3.85 | $0.75 | $-0.81 |
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 14th 2024 | Wells Fargo | Downgrade | Equal Weight | - |
| January 16th 2024 | Morgan Stanley | Downgrade | Equal Weight | $10.4← $9.2 |
| October 13th 2023 | Morgan Stanley | Upgrade | Overweight | $9.2← $3.7 |
| September 15th 2023 | Goldman | Upgrade | Neutral | $9.25← $3.5 |
| July 17th 2023 | Deutsche Bank | Upgrade | Hold | - |
| June 16th 2023 | Wells Fargo | Initiation | Overweight | $17 |
| June 16th 2023 | JP Morgan | Upgrade | Overweight | $10← $3.3 |
| May 31st 2023 | UBS | Initiation | Buy | - |
| January 6th 2023 | Morgan Stanley | Downgrade | Underweight | - |
| December 16th 2022 | Goldman | Downgrade | Sell | - |
| November 15th 2022 | Stifel | Downgrade | Hold | - |
| November 15th 2022 | Citigroup | Downgrade | Sell | - |
| October 24th 2022 | Deutsche Bank | Downgrade | Sell | $150← $196 |
Earnings History & Surprises
MOREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 29, 2024 | $-1.33 | $-0.59 | +55.6% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-1.20 | $-2.10 | -75.0% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $0.08 | $0.36 | +350.0% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-1.72 | $-0.87 | +49.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-1.70 | $-0.54 | +68.2% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.48 | $-0.33 | +31.2% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.42 | $2.41 | +673.8% | ✓ BEAT |
Q4 2022 | Nov 16, 2022 | $-0.39 | $-0.90 | -130.8% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.27 | $-1.72 | -537.0% | ✗ MISS |
Q2 2022 | Jun 23, 2022 | — | $-1.50 | — | — |
Q2 2022 | May 4, 2022 | $-0.61 | $-1.01 | -65.6% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.64 | $-0.83 | -29.7% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $-0.47 | $0.15 | +131.9% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $-0.20 | $-0.32 | -60.0% | ✗ MISS |
Q1 2021 | Mar 15, 2021 | $-0.57 | $-0.15 | +73.7% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $-0.56 | $-0.58 | -3.6% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-2.00 | $-0.40 | +80.0% | ✓ BEAT |
Q2 2020 | May 6, 2020 | $1.09 | $1.53 | +40.4% | ✓ BEAT |
Q1 2020 | Mar 18, 2020 | — | $-0.45 | — | — |
Q4 2019 | Oct 29, 2019 | $-0.28 | $-0.21 | +25.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about MOR
What is MOR's current stock price?
What is the analyst price target for MOR?
What sector is MorphoSys AG in?
What is MOR's market cap?
Does MOR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MOR for comparison